UBS Maintains Neutral on Sabra Health Care REIT, Raises Price Target to $22

Benzinga Newsdesk www.benzinga.com Positive 71.1%

Neg 0% Neu 0% Pos 71.1%

UBS analyst Michael Goldsmith maintains Sabra Health Care REIT (NASDAQ:SBRA) with a Neutral and raises the price target from $21 to $22.